NovoCure (NVCR) EBITDA Margin (2014 - 2026)

NovoCure (NVCR) posted EBITDA Margin of 5.75% for Q2 2026, up 85.15% sequentially from 38.73% in Q1 2026, and up 1913.0% YoY from 0.29% in Q2 2025.

NovoCure (NVCR) EBITDA Margin (2014 - 2026) Analysis & Trends

NovoCure has reported EBITDA Margin for 13 years, with the latest figure at 5.75% in Q2 2026.

Quarterly EBITDA Margin rose 1913.0% year-over-year to 5.75% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 22.08% (up 534.0% YoY) and the FY2025 annual result came in at 23.47%, up 470.0% from the prior year.
EBITDA Margin grew to 5.75% in Q2 2026 per NVCR's latest filing, from 38.73% in the prior quarter.
Over five years, EBITDA Margin peaked at 0.59% in Q1 2022 and troughed at 49.71% in Q2 2023.
A 5-year average of 27.89% and a median of 24.66% in 2025 frame the typical range for EBITDA Margin.
The sharpest annual moves came in 2023 and 2024: EBITDA Margin plunged 4872 bps in 2023, then jumped 2738 bps in 2024.
Over 5 years, EBITDA Margin stood at 33.46% in 2022, then decreased by 16 bps to 38.66% in 2023, then retreated by 2 bps to 39.25% in 2024, then soared by 41 bps to 23.17% in 2025, then surged by 75 bps to 5.75% in 2026.
According to Business Quant data, EBITDA Margin over the past three periods registered 5.75%, 38.73%, and 23.17% for Q2 2026, Q1 2026, and Q4 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Abbott Laboratories	199.61 Bn	194.01 Bn	7.27 Bn	13.44%
2	Stryker	127.81 Bn	124.34 Bn	4.50 Bn	25.18%
3	Medtronic	119.04 Bn	109.82 Bn	6.41 Bn	19.10%
4	Boston Scientific	73.68 Bn	73.14 Bn	3.85 Bn	21.65%
5	Edwards Lifesciences	51.96 Bn	47.71 Bn	1.35 Bn	29.48%
6	Dexcom	34.36 Bn	32.41 Bn	830.00 Mn	24.33%
7	GE HealthCare Technologies	33.83 Bn	31.72 Bn	2.18 Bn	13.96%
8	Koninklijke Philips	26.36 Bn	23.04 Bn	4.55 Bn	10.30%
9	Steris	23.06 Bn	22.58 Bn	684.20 Mn	19.15%
10	NovoCure	2.05 Bn	1.61 Bn	142.48 Mn	-5.75%

Download Data